Ascletis Pharma (HKG:1672) said it has dosed the first patients in its US clinical study for the combination of ASC47 and semaglutide for weight loss patients who do not have type 2 diabetes.
ASC47 is indicated for obese patients and adipose tissue or body fat, according to a Tuesday filing with the Hong Kong bourse.
The drug reduced body weight by about 57% and preserved muscles in diet-induced obese mouse models, the filing said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。